Breast Cancer Therapeutics in Major Developed Markets Trends to 2021 2 | Page 2

- What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational drug candidates are being
evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new
combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy
drug candidates.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were
highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of
action?
- How do other factors, such as average trial duration and trial size influence the costs and risks
associated with product development?
Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets
is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight major markets?
Rising breast cancer incidence and new product approvals will lead to significant market growth over
the forecast period, despite generic sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing
drugs?
- Which patent expirations will have the most significant impact on the market?

Reasons to buy

This report will enable you to - Understand the clinical context of breast cancer by considering symptoms, etiology,
pathophysiology, epidemiology, diagnosis, and treatment options.